Darren Denjay Pan, MD, on Multiple Myeloma: Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy
2023 ASH
Darren Denjay Pan, MD, of Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses his findings on risk assessment of CAR T-cell therapy for patients with multiple myeloma. Higher fibrinogen and ferritin values at baseline were associated with inferior overall survival after CAR T-cell therapy, even after controlling for tumor burden. Higher baseline absolute lymphocyte count was also associated with higher risk and grade of immune effector cell–associated neurotoxicity syndrome, an important toxicity to consider for patients receiving CAR T (Abstract 92).
The ASCO Post Staff
Andrew Srisuwananukorn, MD, of The Ohio State University Comprehensive Cancer Center, discusses a novel artificial intelligence model that can distinguish between prefibrotic primary myelofibrosis and essential thrombocythemia. This proposed model may assist clinicians in identifying patients who may benefit from disease-specific therapies or enrollment in clinical trials (Abstract 901).
The ASCO Post Staff
Adam S. Kittai, MD, of The Ohio State University, discusses his data supporting the use of CAR T-cell therapy for patients with Richter’s transformation. Given the high response rate to CD19 CAR T-cell treatment, along with early relapse in most patients, allogeneic stem cell transplantation at response should also be considered, he says (Abstract 108).
The ASCO Post Staff
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses phase I/II findings of the BRUIN study on the use of pirtobrutinib after covalent Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The results suggest that continuing BTK pathway inhibition following a covalent BTK inhibitor may be an important sequencing approach to consider in the treatment of CLL/SLL (Abstract 325).
The ASCO Post Staff
Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781, 425).
The ASCO Post Staff
Jonathon B. Cohen, MD, of Winship Cancer Institute, Emory University, discusses safety and efficacy findings from the phase I/II BRUIN study. The trial found that pirtobrutinib continues to demonstrate durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma (Abstract 981).
